RS
BCRX icon

R Squared’s BioCryst Pharmaceuticals BCRX Stock Holding History

R Squared’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$203K Buy
+20,263
New +$183K 0.11% 342
2025
Q4 		– Sell
-21,672
Closed -$164K – 538
2025
Q3 		$164K Buy
+21,672
New +$180K 0.07% 405
2025
Q2 		– Sell
-11,670
Closed -$87.5K – 477
2025
Q1 		$87.5K Buy
11,670
+5,335
+84% +$43K 0.09% 234
2024
Q4 		$47.6K Buy
+6,335
New +$48.1K 0.05% 514

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

R Squared's BCRX Position: Q2 2026 in Review

R Squared opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 20,263 shares worth $203K. The stake represents 0.11% of the portfolio and ranks #342 among its holdings. This is a return to the name: R Squared previously reported a position in BCRX as recently as Q3 2025.

R Squared first reported a position in BCRX in Q4 2024 and has held it in 4 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • R Squared held 20,263 shares of BioCryst Pharmaceuticals worth $203K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new R Squared position in Q2 2026.
  • BioCryst Pharmaceuticals made up 0.11% of R Squared's portfolio in Q2 2026, its #342 holding.
  • R Squared first reported a position in BioCryst Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.